Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseases. With several programs in clinical trials as well as in research and preclinical development, Abivax’s pipeline is strong and diversified addressing many unmet medical needs. Abivax is currently targeting different inflammatory diseases within its clinical trial program with lead compound obefazimod: 1) Treatment Inflammatory Bowel Disease (IBD), specifically ulcerative colitis and Crohn's disease 2) Treatment of rheumatoid arthritis The second drug candidate, ABX196, is being tested in a clinical study for the treatment of liver cancer (HCC).